NHS England has announced a halt to new referrals for gender-affirming hormone treatment for 16 and 17-year-olds after the findings of the 2024 Cass Review raised concerns about the treatment's efficacy and safety. Previously, these treatments had been accessible to adolescents diagnosed with gender dysphoria, provided they met certain medical criteria. This latest decision emphasizes a need for a more cautious approach in providing care for transgender youth.

In the review, Baroness Hilary Cass highlighted the importance of prioritizing the well-being and mental health of children undergoing gender care. Her recommendations focus on implementing a more thorough evaluation process before administering hormone treatments, which can induce irreversible physical changes. The necessity of ensuring that participants fully understand the consequences and implications of undergoing such treatments has also been stressed.

The suspension is likely to affect many young individuals who are seeking gender affirmation through medical interventions. With the evolving landscape of gender care, this decision invites further discussions on how best to support young people navigating their gender identity while ensuring their long-term health and safety.